Previous studies have analyzed the remodeling effect of metformin on gut microbiota and its metabolites and revealed that glycoursodeoxycholic acid (GUDCA) and intestinal farnesoid X receptor (FXR) are new targets for treating metabolic diseases associated with obesity
Locking or catching of the knee joint
Meanwhile, supply security for glucagon-like peptide-1 (GLP-1) agents, stricter reimbursement discussions, and an evolving biosimilar pipeline shape the competitive climate Key Report Takeaways By drug class, oral agents retained 46.95% revenue share in 2025, whereas non-insulin injectables are projected to rise at a 9.74% CAGR through 2031
Rashidy-Pour A, Pahlevani P, Vaziri A, Shaigani P, Zarepour L, Vafaei AA, et al
[Abstract] Biochem Biophys Res Commun